IS6. Treatment-Resistant Depression: United States and European Perspectives
Supported by the International Academy for Biomedical and Drug Research

IS7. A Decade of Serotonin Studies: Beyond Depression
Supported by Eli Lilly and Company

1. OCD: Serotonin Specificity Sans Pareil John H. Greist, M.D.


2. Panic Disorder: Etiology and Treatment Mark H. Pollack, M.D.


3. PTSD and Serotonin: Pathopysiology and Treatment Dennis S. Charney, M.D.


4. Dysthymic Disorder: SSRI Treatment Update David L. Dunner, M.D.


5. Premenstrual Dysphoric Disorder: A Role for Serotonin? Tana A. Grady-Weliky, M.D.

IS8. Optimizing Treatment Outcome in Depression
Supported by Organon Inc.

1. Approaches to the Enhancement of Patient Compliance Pedro L. Delgado, M.D.


2. Management of Nonresponse and Intolerance: Switching Strategies Maurizio Fava, M.D.


3. Combined Drug Treatments: Pros and Cons J. Craig Nelson, M.D.


4. Clinical Issues in Long-Term Treatment With Antidepressants John M. Zajecka, M.D.


5. Combining Psychotherapy and Pharmacotherapy: What Are the Advantages? Ellen Frank, Ph.D.

9 a.m.-4 p.m.
CME Courses 21-25

11 a.m.-5 p.m.
Exhibits Open
Publishers' Bookfair Open

12:30 p.m.-1:30 p.m.
Business Meeting and Forum (Voting Members Only)

1 p.m.-5 p.m.
CME Courses 26-30

1:30 p.m.-4:30 p.m.
Industry-Supported Symposia IS9. Mood and the Mind: The Science and Art of New and Emerging Treatment Alternatives
Supported by Janssen Pharmaceutica and Research Foundation

1. The Role of Early Adverse Life Experience in the Development of Mood Disorders Charles B. Nemeroff, M.D.


2. Bipolar Disorder and the Effectiveness of Atypical Antipsychotics K.N. Roy Chengappa, M.D.


3. What Can We Expect From New Therapeutic Approaches to Schizoaffective and Mood Disorders? Jack M. Gorman, M.D.


4. The Anxiety/Depression Dimension of Schizophrenia: How Important Is It? Lili C. Kopala, M.D.


5. Polypharmacy: New Ways of Combining Drug Therapies for Better Results S. Nassir Ghaemi, M.D.

IS10. Anxiety and Depression in the Adolescent: Clinical Implications of Emerging Data
Supported by SmithKline Beecham Pharmaceuticals

1. Current Status of the Diagnosis and Treatment of Adolescent Depression Karen D. Wagner, M.D.


2. Developments in the Treatment of Adolescent Depression Rachel G. Klein, Ph.D.


3. Treatment of the Adolescent With OCD Henrietta L. Leonard, M.D.


4. Social Phobia/Social Anxiety Disorder Stanley P. Kutcher, M.D.


5. Safety Considerations for the Use of Antidepressants in Children and Adolescents Neal D. Ryan, M.D.

IS11. Prodromal Signs: Crucial Information at Both the Theoretical and Practical Level
Supported by Synthelabo

1. Cognitive Function and the Course of Schizophrenia Herbert Y. Meltzer, M.D.


2. Predicting Schizophrenia Michael Davidson, M.D.


3. Prepsychotic Intervention in Schizophrenia: A Stitch in Time? Patrick D. McGorry, Ph.D.


4. Prodromal Signs: Crucial Information at Both the Theoretical and Practical Levels Yves Lecrubier, M.D.


5. The Prodrome: Clinical Features and Early Detection Thomas H. McGlashan, M.D.

IS12. Are Atypical Antipsychotics Also Mood Stabilizers?
Supported by Eli Lilly and Company

1. Pharmacologic Mechanisms of Mood Stabilization Among Atypical Antipsychotics Paul E. Keck Jr., M.D.


2. Atypical Antipsychotics: Treatment of Acute Mania Susan L. McElroy, M.D.


3. Atypical Antipsychotics: Treatment of Depression Richard C. Shelton, M.D.


4. Efficacy and Tolerability of Maintenance Pharmacotherapy in Bipolar Disorders John M. Zajecka, M.D.


5. Health Beliefs and Compliance in Bipolar Disorder Peter J. Weiden, M.D.

IS13. Complexity: Pharmacologic Management Issues in BPD Association for Research in Personality Disorders
Supported by Glaxo Wellcome Inc.

1. The Psychobiology of BPD Larry J. Siever, M.D.


2. Algorithms for the Pharmacologic Treatment of BPD Paul H. Soloff, M.D.


3. Dialectical Behavior Therapy and Pharmacotherapy in BPD Marsha M. Linehan, Ph.D.


4. How "Meanings" Complicate Pharmacologic Management of Patients With BPD John G. Gunderson, M.D.


5. Psychotherapy/Psychopharmacology Split in the Treatment of BPD Kenneth R. Silk, M.D.

2:30 p.m.-4 p.m.
Lecture L1. False Memory Lawsuits: The Weight of the Scientific and Legal Evidence
Daniel Brown, Ph.D., Alan W. Scheflin, and D. Corydon Hammond, Ph.D., AAPL/APA's Manfred S. Guttmacher Award Lecture

5 p.m.-6:30 p.m.
Opening Session and Presidential Address (paper no. 1)

7 p.m.-10 p.m.
Industry-Supported Symposia IS14. Clinical Frontiers in the Sleep/Psychiatry Interface
Supported by Wyeth-Ayerst Laboratories

1. Insomnia and Hypersomnolence: Old Problems With Newer Treatments Karl Doghramji, M.D.


2. Emerging Links Between Depression and Sleep J. Christian Gillin, M.D.


3. Management of Sleep Disturbances in PTSD Thomas C. Neylan, M.D.


4. Pain and Sleep: Neurobiological and Clinical Issues Mitchell J.M. Cohen, M.D.

IS. 15 Depression: Achieving Remission and Compliance: Clinical Challenges and Solutions
Supported by Bristol-Myers Squibb

1. Selecting the Right Antidepressant for Your Patient Norman Sussman, M.D.


2. Psychotherapy of Chronic Depression: Efficacy, Tolerability, Compliance, and Cost John C. Markowitz, M.D.


3. Chronic Depression: Psychotherapy and Pharmacotherapy: Additive or Synergistic? Martin B. Keller, M.D.


4. Maximizing Response in Partial- and Nonresponders to Antidepressants Russell T. Joffe, M.D.

IS16. Longitudinal Aspects of Alzheimer's Disease
Supported by Eisai Inc. and Pfizer Inc.

1. The Pre-Alzheimer's Disease Condition John C. Morris, M.D.


2. Behavior Management Over the Course of Alzheimer's Disease Jeffrey L. Cummings, M.D.


3. Modeling Progression: Implications for Treatment Rachelle S. Doody, M.D.


4. Disease-Modifying Agents and Study Designs Ronald C. Peterson, M.D.


5. Management by Stage of Alzheimer's Disease Peter V. Rabins, M.D.

IS17. Suicide: Clinical/Risk Management Issues for Psychiatrists
Supported by Suicide Research Division of the National Mental Illness Screening Project, the McLean Hospital Bipolar and Psychotic Disorders Program, and Solvay Pharmaceuticals Inc.

1. A Protocol for the Assessment of Suicide Douglas G. Jacobs, M.D.


2. Profiles of Completed Suicide Jan A. Fawcett, M.D.


3. Lithium Discontinuation and Suicide Ross J. Baldessarini, M.D.


4. Bipolar Disorder and Suicide Kay R. Jamison, Ph.D.


5. Suicide, Assisted Suicide, and Medical Illness Herbert Hendin, M.D.


6. F. Liability and Suicide Thomas G. Gutheil, M.D.

IS18. Optimizing Wellness Across the Life Cycle of Schizophrenia
Supported by U.S. Pharmaceuticals, Pfizer Inc.

1. Managing the First Episode John M. Kane, M.D.


2. Meeting Long-Term Treatment Goals: Relapse Prevention and More Nina R. Schooler, Ph.D.


3. Improving Compliance and Building Alliances Peter J. Weiden, M.D.


4. Schizophrenia Toward the End of the Life Cycle Trey Sunderland, M.D.


5. Morbidity and Mortality in Schizophrenia Daniel E. Casey, M.D.

Media Sessions
Session 1. A Contemporary Perspective on Relationships

1. In the Company of Men

Session 2. Bertolucci's The Last Emperor: Multiple Takes, A Psychoanalytic, Cinematic, and Historic Exploration
Forum for the Psychoanalytic Study of Film

2. The Last Emperor